Download the app
App StorePlay Store
Beige
Login
← All tags

organon

Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval

Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval

Sun Pharmaceutical Industries is exploring multiple financing routes for its proposed $12 billion acquisition of Organon & Co. Reports say lenders are considering swapping Organon bondholders into Sun Pharma debt, including a possible euro-denominated bond, while Sun Pharma also plans to raise $3 billion to $4 billion in offshore loans. Deal approvals are expected by December.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Sun Pharma jumps into global top 25 as it buys Organon for 11.75 billion

Sun Pharma jumps into global top 25 as it buys Organon for 11.75 billion

Sun Pharma’s acquisition of Organon in a record $11.75 billion deal propels the company into the world’s top 25 pharma players. While chairman Dilip Shanghvi is excited by the leap in scale and ambition, the moment also carries anxiety—highlighting how even “winning” mergers demand careful execution.

Summarised by Beize from a story on The Economic Times on 6 May 2026

Your news, in seconds

App StorePlay Store
Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

Sun Pharma’s $11.75 billion acquisition of Organon & Co is set to expand its global footprint, commercial reach, and product diversification, including women’s health and biosimilars. The move aims to strengthen long-term growth, but success will hinge on how smoothly management integrates Organon’s operations and controls the deal’s debt burden.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma buys Organon to boost oncology dermatology and women health fast

Sun Pharma buys Organon to boost oncology dermatology and women health fast

Sun Pharma is strengthening its global footprint with the acquisition of New Jersey based Organon. The deal expands its portfolio across dermatology, oncology, and women’s health while creating a route into markets such as China and Brazil. With strong finances underpinning the move, Sun expects quicker returns as it scales the combined capabilities and reach.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma to buy Organon for 11.75 billion all cash deal

Sun Pharma to buy Organon for 11.75 billion all cash deal

Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash transaction worth about $11.75 billion including debt. Sun will buy every outstanding Organon share for $14.00 each, giving it full ownership of a company known for women’s health, biosimilars, and established therapies.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma to acquire Organon for 12 5 billion its biggest deal yet

Sun Pharma to acquire Organon for 12 5 billion its biggest deal yet

Sun Pharma is set to buy US drugmaker Organon for $12.5 billion, expected to be decided at a board meeting over the weekend. The Mumbai-based company will beat the EQT-Gruenthal consortium, paying $4.5 billion for Organon’s equity while taking on $8.5 billion of debt, with an announcement likely tonight or by Monday.

Summarised by Beize from a story on The Economic Times on 26 Apr 2026

Never miss a story

App StorePlay Store
Sun Pharma bids $13 billion for Organon to leap into global branded drugs

Sun Pharma bids $13 billion for Organon to leap into global branded drugs

Sun Pharmaceutical has made a bold $13 billion bid for US firm Organon & Co., signaling its biggest push to shift from generics toward branded and innovative medicines. Sun is competing with other bidders for Organon, and a successful deal would effectively merge Organon into Sun Pharma, reshaping its global ambitions.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play